BLUE.O
Latest Trade
31.10USDChange
2.98(+10.60%)Volume
5,898,034Today's Range
-
31.1452 Week Range
-
76.00As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 28.12 |
|---|---|
Open | 28.24 |
Volume | 5,898,034 |
3M AVG Volume | 37.70 |
Today's High | 31.14 |
Today's Low | 27.43 |
52 Week High | 76.00 |
52 Week Low | 24.24 |
Shares Out (MIL) | 67.14 |
Market Cap (MIL) | 1,888.01 |
Forward P/E | -2.32 |
Dividend (Yield %) | -- |
Bluebird Bio Reports Q4 And Full Year 2020 Financial Results
Bluebird Bio Inc - Anticipates That Cash, Cash Equivalents, Marketable Securities Were About $1.3 Bln As Of December 31, 2020
Bluebird Bio To Separate Oncology Business Into Independent Company
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Industry
Biotechnology & Drugs
Contact Info
60 Binney St
CAMBRIDGE, MA
02142-1512
United States
+1.339.4999300
http://www.bluebirdbio.comExecutive Leadership
Daniel S. Lynch
Independent Chairman of the Board
Nick Leschly
President, Chief Executive Officer, Director
William D. Baird
Chief and Principal Financial Officer, Interim Principal Accounting Officer
Jason F Cole
Chief Operating Officer and Legal Officer, Secretary
Philip D. Gregory
Chief Scientific Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 7.53 |
Price To Book (MRQ) | 1.38 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -40.16 |
Return on Equity (TTM) | -35.27 |
Bluebird bio Inc plans to spin off its cancer drugs unit into a new, publicly traded company later this year to focus on rare genetic diseases, the company said on Monday.
Bluebird bio Inc plans to spin off its cancer drugs unit into a new, publicly traded company later this year, the Wall Street Journal reported on Monday.
Bluebird bio Inc <BLUE.O> said on Monday Bristol Myers Squibb Co <BMY.N> would give it a one-time payment of $200 million to buy out obligations for future royalties on sales outside the United States of two cancer therapies being developed by them.
Bluebird bio Inc said on Monday partner Bristol Myers Squibb Co would pay $200 million to buy out future royalty obligations on sales of two therapies being developed by the companies.
* BLUEBIRD BIO ANNOUNCES AMENDED BCMA CAR-T COLLABORATION AGREEMENT
* BLUEBIRD BIO INC - NICK LESCHLY, CO'S CHIEF EXECUTIVE OFFICER, REDUCED HIS BASE SALARY BY APPROXIMATELY 100% DURING THIS TWELVE-MONTH PERIOD
* BLUEBIRD BIO PROVIDES ASSESSMENT OF IMPACT OF COVID-19, UPDATE ON BUSINESS OPERATIONS AND CLINICAL PROGRAM DEVELOPMENT
* BLUEBIRD BIO - ON MARCH 6, CO'S UNIT AND APCETH BIOPHARMA GMBH ENTERED INTO AMENDMENT
Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.
Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.
Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.
A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.
A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.
* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO LENTI-D™ FOR THE TREATMENT OF CEREBRAL ADRENOLEUKODYSTROPHY
German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.
German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.
* BLUEBIRD BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS
* BLUEBIRD BIO AND CELGENE CORPORATION ENTER INTO AGREEMENT TO CO-DEVELOP AND CO-PROMOTE ANTI-BCMA CAR T CELL THERAPY BB2121 IN THE UNITED STATES
* BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.